Liver Fibrosis in Type I Gaucher Disease: Magnetic Resonance Imaging, Transient Elastography and Parameters of Iron Storage

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Bohte, Anneloes E ^a   van Dussen, Laura ^a   Akkerman, Erik M ^a   Nederveen, Aart J ^a   Sinkus, Ralph ^b   Jansen, Peter L M ^a   Stoker, Jaap ^a   Hollak, Carla E M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC IMAGING EQUIPMENT; DISEASE SEVERITY; ELASTOGRAPHY; FEMALE; GAUCHER DISEASE; GENE; HEMOCHROMATOSIS; HFE GENE; HUMAN; IRON STORAGE; LIVER FIBROSIS; MALE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PILOT STUDY; PROSPECTIVE STUDY; SPLENECTOMY; TREATMENT FAILURE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; ELASTICITY IMAGING TECHNIQUES; FEMALE; GAUCHER DISEASE; HUMANS; INCIDENCE; IRON; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SPLENECTOMY;

EID: 84875027886     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057507     Document Type: Article

References (58)

1. Beutler E, Grabowski GA (2001) Gaucher Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8 ed. New York: McGraw-Hill. 3636.
2. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS, (1974) Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med 291: 989-993.
3. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, et al. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481-1485.
4. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, et al. (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33-39.
5. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, et al. (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105: 151-156.
6. Lachmann RH, Wight DG, Lomas DJ, Fisher NC, Schofield JP, et al. (2000) Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 93: 237-244.
7. Breiden-Langen CM, Buchsel R, Brambs HJ, Oehlert M, Matern S (1991) Coincidence of Gaucher disease with primary hepatocellular carcinoma. Leber Magen Darm 21: 126, 129-126, 130.
8. de Fost M, vom Dahl S, Weverling GJ, Brill N, Brett S, et al. (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36: 53-58.
9. Erjavec Z, Hollak CE, de Vries EG, (1999) Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Ann Oncol 10: 243.
10. Lee RE, (1982) The pathology of Gaucher disease. Prog Clin Biol Res 95: 177-217.
11. Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, et al. (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84: 208-214.
12. Xu R, Mistry P, McKenna G, Emre S, Schiano T, et al. (2005) Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Semin Liver Dis 25: 226-229.
13. Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D, (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34: 197-200.
14. Shoenfeld Y, Gallant LA, Shaklai M, Livni E, Djaldetti M, et al. (1982) Gaucher's disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med 106: 388-391.
15. Bassan R, Montanelli A, Barbui T, (1985) Interaction between a serum factor and T lymphocytes in Gaucher disease. Am J Hematol 18: 381-384.
16. Brill NE, Mandlebaum FS, Libman E (1905) Primary splenomegaly- Gaucher type. Report on one of four cases occurring in a single generation of one family. Am J Med Sci: 491.
17. Lee RE, Balcerzak SP, Westerman MP, (1967) Gaucher's disease. A morphologic study and measurements of iron metabolism. Am J Med 42: 891-898.
18. Lorber M (1960) The occurrence of intracellular iron in Gaucher's disease. Ann Intern Med. 53[2], 293.
19. Lorber M, Nemes JL, (1967) Identification of ferritin within Gaucher cells. An electron microscopic and immunofluorescent study. Acta Haematol 37: 189-197.
20. Morgan MA, Hoffbrand AV, Laulicht M, Luck W, Knowles S, (1983) Serum ferritin concentration in Gaucher's disease. Br Med J (Clin Res Ed) 286: 1864.
21. Weisberger J, Emmons F, Gorczyca W, (2004) Cytochemical diagnosis of Gaucher's disease by iron stain. Br J Haematol 124: 696.
22. Lorber M, (1970) Adult-type Gaucher's disease: a secondary disorder of iron metabolism. Mt Sinai J Med 37: 404-417.
23. Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, et al. (2008) Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 31: 319-336.
24. Krasnewich D, Dietrich K, Bauer L, Ginns EI, Sidransky E, et al. (1998) Splenectomy in Gaucher disease: new management dilemmas. Blood 91: 3085-3087.
25. Ponce E, Moskovitz J, Grabowski G, (1997) Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood 90: 43-48.
26. de Fost M, van Noesel CJ, Aerts JM, Maas M, Poll RG, et al. (2008) Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 93: 1119-1120.
27. Hollak CE, Belmatoug N, Cole JA, vom Dahl S, Deegan PB, et al. (2012) Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years. Br J Haematol 158: 528-538.
28. Perel Y, Bioulac-Sage P, Chateil JF, Trillaud H, Carles J, et al. (2002) Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy. Pediatrics 109: 1170-1173.
29. EASL clinical practice guidelines for HFE hemochromatosis, (2010) J Hepatol. 53: 3-22.
30. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, (2012) J Hepatol. 56: 908-943.
31. Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, et al. (2010) Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51: 828-835.
32. Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, et al. (2008) Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135: 32-40.
33. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, et al. (2007) Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 5: 1207-1213.
34. Castera L, (2012) Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 142: 1293-1302.
35. Poca M, Puente A, Graupera I, Villanueva C, (2011) Prognostic markers in patients with cirrhosis and portal hypertension who have not bled. Dis Markers 31: 147-154.
36. St Pierre TG, Clark PR, Chua-Anusorn W, (2005) Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci 1054: 379-385.
37. St Pierre TG, Clark PR, Chua-Anusorn W, Fleming AJ, Jeffrey GP, et al. (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105: 855-861.
38. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, et al. (2005) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106: 1460-1465.
39. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, et al. (2004) Non-invasive assessment of hepatic iron stores by MRI. Lancet 363: 357-362.
40. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, et al. (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29: 1705-1713.
41. Boursier J, Zarski JP, de Ledinghen, V, Rousselet MC, Sturm N, et al. (2012) Determination of reliability criteria of liver stiffness evaluation by transient elastography. Hepatology.
42. Garteiser P, Sahebjavaher RS, Ter Beek L, van Beers BE, Salcudean SE, et al. (2012) Rapid 3D motion-encoding using steady-state FFE pulse sequence: application towards multifrequency MR rheology. Proc Intl Soc Mag Reson Med 20: 3423.
43. Sinkus R, Siegmann K, Xydeas T, Tanter M, Claussen C, et al. (2007) MR elastography of breast lesions: understanding the solid/liquid duality can improve the specificity of contrast-enhanced MR mammography. Magn Reson Med 58: 1135-1144.
44. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, Out JM, Donker-Koopman WE, et al. (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278: 40911-40916.
45. Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak CE, et al. (2007) Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381: 136-139.
46. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, et al. (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273: 25680-25685.
47. Nederlandse Internisten Vereniging, Nederlandse Vereniging voor Klinische Chemie en Laboratoriumgeneeskunde, Vereniging Artsen Laboratoriumdiagnostiek (2007) Dutch Guideline Hereditary Hemochromatosis.
48. Hughes D, Cappellini MD, Berger M, Van Droogenbroeck J, de Fost M, et al. (2007) Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 138: 676-686.
49. Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, et al. (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90: 52-60.
50. Rodrigue SW, Rosenthal DI, Barton NW, Zurakowski D, Mankin HJ (1999) Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin Orthop Relat Res: 201-207.
51. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, et al. (2011) Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 54: 650-659.
52. Castera L, Vergniol J, Foucher J, Le BB, Chanteloup E, et al. (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 128: 343-350.
53. European Association of the Study of the Liver hepatitis C virus clinical practice guidelines, (2012) Liver Int. 32 (Suppl 1): 2-8.
54. Wang QB, Zhu H, Liu HL, Zhang B (2012) Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology.
55. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS, (2011) Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 328-343.
56. Bassett ML, Halliday JW, Powell LW, (1986) Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6: 24-29.
57. Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, et al. (1998) Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115: 929-936.
58. Lucidarme D, Foucher J, Le BB, Vergniol J, Castera L, et al. (2009) Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology. 49: 1083-1089.